亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial

埃博拉病毒 医学 临床试验 埃博拉疫苗 病毒学 埃博拉病毒 爆发 内科学
作者
Jake Dunning,Foday Sahr,Amanda Rojek,Fiona Gannon,Gail Carson,Baimba Idriss,Thomas Massaquoi,Regina Gandi,Sebatu Joseph,Hassan K. Osman,Timothy Brooks,Andrew J. H. Simpson,Ian Goodfellow,Lucy Thorne,Armando Arias,Laura Merson,L Castle,Rebecca Howell‐Jones,Raul Pardinaz-Solis,Benjamin Hope-Gill
出处
期刊:PLOS Medicine [Public Library of Science]
卷期号:13 (4): e1001997-e1001997 被引量:159
标识
DOI:10.1371/journal.pmed.1001997
摘要

BACKGROUND: TKM-130803, a small interfering RNA lipid nanoparticle product, has been developed for the treatment of Ebola virus disease (EVD), but its efficacy and safety in humans has not been evaluated. METHODS AND FINDINGS: In this single-arm phase 2 trial, adults with laboratory-confirmed EVD received 0.3 mg/kg of TKM-130803 by intravenous infusion once daily for up to 7 d. On days when trial enrolment capacity was reached, patients were enrolled into a concurrent observational cohort. The primary outcome was survival to day 14 after admission, excluding patients who died within 48 h of admission. After 14 adults with EVD had received TKM-130803, the pre-specified futility boundary was reached, indicating a probability of survival to day 14 of ≤0.55, and enrolment was stopped. Pre-treatment geometric mean Ebola virus load in the 14 TKM-130803 recipients was 2.24 × 109 RNA copies/ml plasma (95% CI 7.52 × 108, 6.66 × 109). Two of the TKM-130803 recipients died within 48 h of admission and were therefore excluded from the primary outcome analysis. Of the remaining 12 TKM-130803 recipients, nine died and three survived. The probability that a TKM-130803 recipient who survived for 48 h will subsequently survive to day 14 was estimated to be 0.27 (95% CI 0.06, 0.58). TKM-130803 infusions were well tolerated, with 56 doses administered and only one possible infusion-related reaction observed. Three patients were enrolled in the observational cohort, of whom two died. CONCLUSIONS: Administration of TKM-130803 at a dose of 0.3 mg/kg/d by intravenous infusion to adult patients with severe EVD was not shown to improve survival when compared to historic controls. TRIAL REGISTRATION: Pan African Clinical Trials Registry PACTR201501000997429.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
落后的雨筠完成签到,获得积分10
1秒前
萧雨墨发布了新的文献求助10
4秒前
萧雨墨发布了新的文献求助10
17秒前
abc完成签到,获得积分20
39秒前
d22110652完成签到,获得积分10
40秒前
44秒前
萧雨墨发布了新的文献求助10
49秒前
所所的应助被Lihedou采纳,获得10
50秒前
凡fan完成签到,获得积分10
50秒前
完美世界的应助被amiee采纳,获得10
53秒前
58秒前
高速公鹿发布了新的文献求助10
59秒前
Jun的应助被科研通管家采纳,获得10
1分钟前
1分钟前
Lucas的应助被科研通管家采纳,获得10
1分钟前
abc发布了新的文献求助10
1分钟前
萧雨墨发布了新的文献求助10
1分钟前
Lihedou发布了新的文献求助10
1分钟前
1分钟前
1分钟前
平淡的蓉完成签到,获得积分10
1分钟前
amiee发布了新的文献求助10
1分钟前
乐观老三完成签到 ,获得积分10
1分钟前
烟花的应助被霸气凌珍采纳,获得10
1分钟前
萧雨墨发布了新的文献求助10
1分钟前
1分钟前
傲娇断天完成签到,获得积分10
1分钟前
1分钟前
萧雨墨发布了新的文献求助10
1分钟前
1分钟前
1分钟前
希望天下0贩的0的应助被佳佳采纳,获得10
1分钟前
1874发布了新的文献求助10
1分钟前
萧雨墨发布了新的文献求助10
1分钟前
lili完成签到 ,获得积分10
1分钟前
直率的宛丝完成签到,获得积分10
1分钟前
情怀的应助被1874采纳,获得10
1分钟前
对对对完成签到 ,获得积分10
1分钟前
萧雨墨发布了新的文献求助10
2分钟前
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190117
求助须知:如何正确求助?哪些是违规求助? 9577222
关于积分的说明 21852176
捐赠科研通 7788406
什么是DOI,文献DOI怎么找? 3436259
关于科研通互助平台的介绍 2559994
邀请新用户注册赠送积分活动 2482862